MPH
Venture Partner
Mark Wesson brings extensive expertise across venture capital, healthcare innovation, and operational leadership. With a career spanning biopharmaceutical development, medical devices, and health system strategy, Mark uniquely bridges the perspectives of founders, investors, and clinical stakeholders. He has sourced and screened venture deals, advised early-stage startups, and designed growth strategies that integrate both clinical relevance and commercial scalability. His experience as a fractional CFO, startup advisor, and healthtech operator enables him to provide value well beyond traditional investment roles, helping portfolio companies build sustainable business models while advancing patient care.
Mark’s motivation to join GHIF stems from his belief in venture capital as a catalyst for impact. He is motivated by the belief that capital should not only generate returns but also improve lives. He also enjoys the opportunity to make evidence-based impact with early-stage health innovation, accelerate breakthroughs in care, and drive meaningful, measurable outcomes. GHIF’s mission resonated with his values, aligning purpose-driven investing with a clear mandate to support transformative startups in life sciences and healthcare delivery.
With his diverse background, Mark brings a multidimensional approach to investing. He combines the rigor of due diligence and market analysis with hands-on experience in operations and finance. At GHIF, he plans to leverage this breadth to source and evaluate mission-aligned startups, provide founders with financial and strategic guidance, and help bridge clinical adoption with commercial viability. His role is not just to identify promising ventures but to actively shape them into impactful, enduring companies, advancing GHIF’s mission to deliver both financial returns and meaningful global health outcomes.